- Home
- BCYC vs DIAX Comparison
BCYC vs DIAX Comparison
Compare BCYC & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCYC
- DIAX
- Stock Information
- Founded
- BCYC 2009
- DIAX 2005
- Country
- BCYC United Kingdom
- DIAX United States
- Employees
- BCYC N/A
- DIAX N/A
- Industry
- BCYC Biotechnology: Pharmaceutical Preparations
- DIAX Finance Companies
- Sector
- BCYC Health Care
- DIAX Finance
- Exchange
- BCYC Nasdaq
- DIAX Nasdaq
- Market Cap
- BCYC 449.5M
- DIAX 535.3M
- IPO Year
- BCYC 2019
- DIAX N/A
- Fundamental
- Price
- BCYC $6.30
- DIAX $14.55
- Analyst Decision
- BCYC Buy
- DIAX
- Analyst Count
- BCYC 11
- DIAX 0
- Target Price
- BCYC $20.73
- DIAX N/A
- AVG Volume (30 Days)
- BCYC 345.2K
- DIAX 96.6K
- Earning Date
- BCYC 10-30-2025
- DIAX 01-01-0001
- Dividend Yield
- BCYC N/A
- DIAX 7.93%
- EPS Growth
- BCYC N/A
- DIAX N/A
- EPS
- BCYC N/A
- DIAX N/A
- Revenue
- BCYC $28,339,000.00
- DIAX N/A
- Revenue This Year
- BCYC N/A
- DIAX N/A
- Revenue Next Year
- BCYC N/A
- DIAX N/A
- P/E Ratio
- BCYC N/A
- DIAX N/A
- Revenue Growth
- BCYC N/A
- DIAX N/A
- 52 Week Low
- BCYC $6.10
- DIAX $12.80
- 52 Week High
- BCYC $21.60
- DIAX $15.12
- Technical
- Relative Strength Index (RSI)
- BCYC 36.23
- DIAX 39.13
- Support Level
- BCYC $6.17
- DIAX $14.63
- Resistance Level
- BCYC $6.89
- DIAX $14.83
- Average True Range (ATR)
- BCYC 0.46
- DIAX 0.16
- MACD
- BCYC -0.07
- DIAX -0.05
- Stochastic Oscillator
- BCYC 7.91
- DIAX 13.88
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.